THE UNIVERSITY OF FLORIDA received a $12 million gift from The Harris Rosen Foundation to advance innovative brain tumor immunotherapy research and care at the University of Florida Health and to launch an unprecedented partnership for the development of novel brain tumor treatments. The Rosen gift is the cornerstone of a $100 million fundraising commitment to support the ReMission Alliance Against Brain Tumors, a collaborative initiative led by the University of Florida to unite neuro-oncology physicians and scientists in research and clinical trials.
The gift was announced recently before the inaugural ReMission Summit for Brain Tumors in Orlando. The University of Florida–organized ReMission Summit brings together more than 100 experts in neuro-oncology, tumor immunology, genetics, artificial intelligence, neuroimaging, and bioinformatics to form a research community focused on achieving transformative outcomes for patients with brain tumors over the next decade. The ReMission Summit also serves as the public forum for the debut of the ReMission Alliance, a multi-institutional research collaborative focused on the advancement of novel immunotherapies for adult and pediatric brain cancers.
Jonathan D. Licht, MD
“Initiatives at the Cancer Center have become a centerpiece of the University of Florida Health’s overall research portfolio, which includes approximately $200 million per year in National Institutes of Health funding and totals $450 million in sponsored program expenditures,” said Jonathan D. Licht, MD, Director of the University of Florida Health Cancer Center. ■